Compare

Phibro Animal Health/$PAHC

1D1W1M3M6MYTD1Y5YMAX

About Phibro Animal Health

Phibro Animal Health Corp is a world-wide diversified animal health and mineral nutrition company. It strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. It develop, manufacture and market products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. It has three segments Animal Health, Mineral Nutrition, and Performance Products. Majority of revenue comes from Animal Health segment. Animal health products are anti-bacterials, anticoccidials, nutritional specialty products, and vaccines, and vaccine adjuvants that help improve the animal's health.
Ticker
$PAHC
Sector
Health
Primary listing
NASDAQ
Employees
2,605

PAHC Metrics

BasicAdvanced
$1.4B
14.01
$2.50
0.40
$0.48
1.37%

What the Analysts think about PAHC

Analyst ratings (Buy, Hold, Sell) for Phibro Animal Health stock.
Analyst projections of the future price of Phibro Animal Health stock.

Bulls say / Bears say

The business entered FY27 with momentum: FY26 sales rose 17% to $1.52 billion and adjusted EBITDA rose 39% to $255 million; first-quarter sales then grew 6% and adjusted EPS 8% year on year. That points to continued earnings growth after the acquisition-led expansion. (Phibro Animal Health, Business Wire)
First-quarter sales rose in all three divisions: Animal Health added $9.6 million, Mineral Nutrition $10.6 million and Performance Products $2.7 million. That spread gives Phibro several sources of growth rather than relying on one segment alone. (Business Wire)
Closing the Chicago Heights facility and moving production elsewhere is expected to improve efficiency and add $15 million to $20 million in annual benefit from FY28. That offers a potential margin tailwind once the transition is complete. (Stock Analysis)
Brazil's regulatory shift puts a high-margin revenue stream at risk: virginiamycin sales there were about $27 million in FY26, and first-quarter sales fell $5.2 million as rules changed. Approval for therapeutic claims remains uncertain. (Stock Titan, Business Wire)
FY27 guidance implies just 4% sales growth and 3% adjusted EBITDA growth at the midpoint, versus FY26 growth of 17% and 39% respectively. This signals a sharp slowdown from the recent pace. (Phibro Animal Health)
Working-capital and inventory conversion remain a management priority; trailing-year free cash flow was $21.7 million against $739.6 million of debt and 2.9 times gross leverage. Modest cash generation could slow debt reduction. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.

PAHC Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

PAHC Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.